Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, hurdles that include availability and cost remain to its widespread ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas ... Patients with lymphoma whose disease has returned after several lines of therapy have a very poor prognosis, with ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas ... Patients with lymphoma whose disease has returned after several lines of therapy have a very poor prognosis, with ...

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.

Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Now, a team led by researchers from the Mayo Clinic looks to confirm a more-established correlation among lymphoma overall, as well as its subtypes. Twenty-three gene expression levels were ...

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.

Hodgkin’s lymphoma is a B-cell lymphoma. Non-Hodgkin’s lymphoma ... lymphoma that someone is diagnosed with will determine the prognosis (outcomes). However, when looking at T-cell lymphomas ...

While the trial was not designed to evaluate efficacy, Ghobadi and colleagues said that responses were observed across B-cell lymphoma histologies among those treated with the combination ...